Althea launches affordable COVID-19 rapid antigen tests

Althea UK and Ireland has revelaed that it is now offering high-quality and cost-effective SARS-CoV-2 Rapid Antigen Tests. 

The antibody test – manufactured by Roche – can help detect SARS-CoV-2 infection in those suspected to carry the virus with results available in 15 minutes. The test can be used for both symptomatic and asymptomatic individuals.

Althea hopes that the new service, which is available for pharmacies, dentists, hospitals and clinics, as well as hospital support companies, will provide a valuable initial screening test for staff who might be exposed to COVID-19 or work in high-risk environments. 

CEO David Rolfe said: “As COVID-19 continues to spread, and while vaccinations are being rolled out, testing remains crucial to contain the spread of COVID-19. We are pleased to be able to offer the Roche rapid antigen tests to support those providing vital services across the country with a reliable, high-quality testing option at an affordable price. At a time where budgets are stretched and health services are under pressure, as a trusted partner to many hospitals in the UK, we want to do our part in supporting those working on the frontline.” 

Althea manages and maintains medical technology in hospitals and is entirely vendor-independent, meaning they can combine the best technology from across all manufacturers. The company aims to support hospitals with increased capacity and new technology delivered in the most cost effective and clinically effective way.

During COVID-19, Althea played a key role in setting up equipment at the London NHS Nightingale Hospital. Specialist engineers from Althea have unpacked, built, tested and commissioned over 2,750 pieces of equipment to be used at the emergency hospital, and have helped advise the NHS procurement team in sourcing vital equipment

Today the company is providing rapid COVID-19 tests to help further support the national response to COVID-19.

The test has a sensitivity of 96.52% and a specificity of 99.68% and helps to detect antibodies in individuals who have been exposed to the virus. Tests are for professional use and should be administered by healthcare or trained occupational health staff.